Strategic partnerships Opportunity: Despite a small team, GO Therapeutics has a history of high-profile collaborations with Roche and Astellas, indicating openness to licensing, co-development, or research collaborations. Sales outreach could target BD at large pharma and mid-sized biotech firms for co-development or strategic licensing of their glycoprotein-targeted antibodies and immuno-oncology platforms.

Immuno-oncology focus Opportunity: GO Therapeutics is actively developing novel immuno-oncology antibodies and modalities (TCBs, CAR-T, ADCs) targeting cancer-specific glycoproteins. Potential sales angles include partnering for preclinical-to-clinical support, platform licensing, or contract research services to accelerate antibody discovery, optimization, and preclinical testing for IO programs.

Early-stage traction Opportunity: Revenue reported is modest and funding is limited, suggesting GO is in early-stage growth with a need for non-dilutive or strategic funding, collaborations, or CRO partnerships to advance pipelines. BD could position services or collaborations as a value-add to accelerate milestones and de-risk platform validation for potential funders.

Targeted capabilities Opportunity: Their focus on high-affinity antibodies against novel cancer-specific targets offers a niche for specialized contract research, antibody engineering, and glycoproteomics analytics services. Vendors could pitch end-to-end discovery support, affinity maturation, and assay development to de-risk early-stage programs.

Expansion potential Opportunity: With prior licensing partnerships and a strong immuno-oncology alignment, there is room to explore regional collaborations, co-development deals, or licensing of specific targets to expand reach. Proposals could emphasize joint IP strategy, milestone-based payments, and access to GO’s proprietary glycoprotein targets.